Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study
Lecanemab was utilized in appropriate patient populations according to the prescribing information approved by the US Food and Drug Administration. Findings from our study provide first insights into the real-world use of lecanemab in the USA and shed light on the need for increased and timely lecanemab initiation for the long-term management of early AD.
Authors
- Chenyue Zhao
- François Laliberté (ORCID: https://orcid.org/0000-0003-2601-6214)
- Feride Frech (ORCID: https://orcid.org/0000-0002-1992-1112)
- Se Ryeong Jang
- Malena Mahendran
- Kavita V. Nair (ORCID: https://orcid.org/0009-0009-0201-1495)
- Kaixin Zhang (ORCID: https://orcid.org/0009-0003-8194-8046)
- Marwan N. Sabbagh
- Hideki Toyosaki
Institutions
- Barrow Neurological Institute (US)
- Eisai (United States) (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1007/s40120-025-00756-4
- Citations
- 7
- Primary Topic
- Cancer-related cognitive impairment studies
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- Biogen